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Abstract
After several years of steady decline, syphilis is reemerging globally as a public health hazard, especially among people living with
human immunodeﬁciency virus (HIV). Syphilis resurgence is observed mainly in men who have sex with men (MSM), yet other
transmission groups are affected too. In this manuscript, we study the factors associated with syphilis incidence in the Swiss HIV
cohort study in the era of highly effective antiretrovirals. Using parametric interval censored models with ﬁxed and time-varying
covariates, we studied the immunological, behavioral, and treatment-related elements associated with syphilis incidence in 3
transmission groups: MSM, heterosexuals, and intravenous drug users. Syphilis incidence has been increasing annually since 2005,
with up to 74 incident cases per 1000 person-years in 2013, with MSM being the population with the highest burden (92% of cases).
While antiretroviral treatment (ART) in general did not affect syphilis incidence, nevirapine (NVP) was associated with a lower hazard of
syphilis incidence (multivariable hazard ratio 0.5, 95% conﬁdence interval 0.2–1.0). We observed that condomless sex and younger
age were associated with higher syphilis incidence. Moreover, time-updated CD4, nadir CD4, and CD8 cell counts were not
associated with syphilis incidence. Finally, testing frequency higher than the recommended once a year routine testing was
associated with a 2-fold higher risk of acquiring syphilis. Condomless sex is the main driver of syphilis resurgence in the Swiss HIV
Cohort study; ART and immune reconstitution provide no protection against syphilis. This entails targeted interventions and frequent
screening of high-risk populations. There is no known effect of NVP on syphilis; therefore, further clinical, epidemiological, and
microbiological investigation is necessary to validate our observation.
Abbreviations: HIV = human immune deﬁciency virus, ART = antiretroviral treatment, MSM =men who have sex with men, HR =
hazard ratio, SHCS = Swiss HIV Cohort study, HET = heterosexual, IDU = intravenous drug users, NRTI = nucleotide reverse
transcriptase inhibitors, NNRTI = non-nucleotide reverse transcriptase inhibitors, PI = protease inhibitors, NVP = nevirapine, CI =
conﬁdence interval.
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Key Points
 Syphilis coinfection in the HIV infected is rising due to
an increase in condomless sex in the younger MSM
population in Switzerland.
 Antiretrovirals provide no additional protection against
syphilis except for provisional effect of Nevirapine.
 A protective effect of Nevirapine on syphilis has not been
reported in the literature and could be due to confounding
thus requires further investigation.
1. Introduction
Syphilis is a reemerging public health hazard that has been on the
rise in recent years globally[1] and locally in Switzerland.[2] This
is particularly the case for the human immunodeﬁciency virus
(HIV)-infected population, with 1 review placing the mean
prevalence of syphilis in the HIV-infected population at 9.5%.[3]
The importance of syphilis as a coinfection in HIV-infected
individuals does not only stem from the negative effect of syphilis
on the natural course ofHIV infection (manifested as a temporary
reduction in CD4 cells and an elevation in HIV viral load[4,5]) but
also from the enhancement of HIV transmission in individuals
coinfected with syphilis.[6] It is estimated that 60% of syphilis
cases are asymptomatic,[2] and syphilis infection enhances HIV
transmission and other coinfections (e.g., Hepatitis B[7] and
Hepatitis C[8]), which places syphilis coinfection in the forefront
of HIV transmission and public health concerns.
Antiretroviral treatment (ART) has been shown to affect HIV
and some of its coinfections through 3main axes: immunological,
behavioral, and direct. On the immunological front, ART
enhances immune reconstitution in HIV-infected individuals
leading to an enhanced protection against pathogens.[9] More
generally, there is a strong interaction between the immune
system and syphilis (e.g., a lowCD4 cell count is associatedwith a
higher likelihood of developing neurosyphilis[5]).
On the behavioral side, ART inﬂuences sexual risk behavior
differently depending on the setting,[10] with some evidence
pointing toward no change in sexual risk behavior and other
suggesting risk compensation.[11] In the Swiss HIV Cohort Study
(SHCS), a trend of increasing condomless sex in all transmission
groups has been observed. This increase was especially evident in
men who have sex with men (MSM): individuals under ART
treatment in both stable and casual relationships are using
condoms less frequently.[12] Similar patterns of increased
condomless sex among MSM have been observed in the United
States as well.[13]
Finally, ART has a direct effect on HIV coinfections including
herpes simplex virus type 2[14] and Hepatitis B Virus.[15] In
addition, ART has been shown to have a wide array of targets
and functions including activity as antitumor, antibacterial,
antifungal, antimalarial, anti-Severe acute respiratory syndrome
and anti-inﬂuenza agent.[16]
Despite several studies examining the interaction between ART
and syphilis in HIV-infected individuals, the relationship remains
unclear, with associations spanning the entire spectrum, some
positive, others negative, and some showing no inﬂuence. Several
studies suggest that HIV-infected individuals on ART may have
better overall treatment response, including a better outcome in
neurosyphilis,[17–19] lower rates of syphilis serological failure,[20]
shorter time to serological response,[21] and lower adjusted
incidence.[22] In contrast, other studies suggest that ART has no
inﬂuence on syphilis incidence,[23,24] or even increases it,[25–27]
while others suggest no effect of ART on treatment or serological
failure.[28,29]
In light of this complex nature of syphilis coinfection in HIV-
positive individuals, we aimed to examine the factors that affect
syphilis incidence in the SHCS. We used a large MSM cohort
from the SHCS with comprehensive longitudinal data on sexual
behavior, treatment regimens and continuation, demographics,
treatment response, and immunological proﬁles. In addition, we
assessed the incidence of syphilis in other important transmission
groups (heterosexuals [HETs] and intravenous drug users [IDUs]).
We aimed to further disentangle the association between ART and
syphilis and evaluate whether it is due to immunological factors,
behavioral aspects, time trends, or the direct effect of ART.
2. Methods
TheSHCS is a prospective cohortwith ongoing enrollment forHIV-
infected individuals in Switzerland since 1988. Clinical, laboratory,
and sociodemographics information are collected every 6 months.
This includes information about sexual behavior in terms of having
a stable or occasional partner(s) in the past 6 months, and if so,
whether sex was with or without a condom. All participants
provided informed consent, and the study was approved and is
conducted per the guidelines of the ethical committees of the
respective participating center (refer to http://www.shcs.ch/206-
ethic-committee-approval-and-informed-consent for all ethics com-
mittee approvals of the participating centers). The SHCS study was
shown to be highly representative of theHIV-infected population in
Switzerland, including “hard-to-reach” populations.[30]
Annual syphilis testing ceased as of 1998 owing to a steady
decline in the syphilis infection rate in Switzerland and an internal
analysis that revealed that syphilis testing every 2 years imparted
no decrement in incidence.[2] Syphilis testing was restarted in
2004, hence only tests taking place thereafter were included here.
Syphilis testing in the SHCS can be divided into 2 categories:
nontreponemal and treponemal. The nontreponemal branch
contains either Venereal Diseases Research Laboratory or Rapid
plasma regains, and the treponemal branch includes Treponema
pallidum particle agglutination assay/Treponema pallidum
hemagglutination assay, Liaison (CLIA), and Architect (CMIA).
Only individuals with a negative result in a ﬁrst baseline
test according to both methods were included in the analysis.
Individuals with missing tests in either arm were excluded, and a
case was considered positive only if both markers turned
positive.[31] A positive treponemal test with a negative non-
treponemal test was considered evidence for previous infections
and those individuals/observation time were excluded.
We included in the analysis all available individuals meeting
the aforementioned criteria from 2004 to 2014. Owing to the
limited number of syphilis cases in HET and IDU, the analysis
was later restricted to MSM as they account for the vast majority
of cases. This also allowed for a more homogenous population
(and consequently a comparable risk behavior). The observation
time was deﬁned as the time between the ﬁrst negative test and
either the ﬁrst positive syphilis test or the last negative test.
Finally, only individuals who were observed for a year or more
were analyzed. Note that the transmission group of a patient
constitutes the most probable route of HIV infection as declared
jointly by the patient and the clinician.
Shilaih et al. Medicine (2017) 96:2 Medicine
2
3. Statistical analysis
Given the inherent interval-censored nature of syphilis incidence
(imprecise knowledge of the exact point of time where the
infection occurred), we utilized univariable and multivariable
parametric interval-censored models with time-ﬁxed and time-
varying covariates and an exponential hazard function (as in Ref.
[15]). We tested the association of ART (exposure) and syphilis
incidence (outcome variable), where ART was coded in several
hierarchical ways: ART as a binary variable; ART divided into 4
classes of nucleotide reverse transcriptase inhibitors (NRTI), non-
nucleotide reverse transcriptase inhibitors (NNRTI), protease
inhibitors (PI), and other HIV antiretroviral drug classes
(integrase and fusion inhibitors, primarily Raltegravir [87%]);
ART divided into NRTI, PI, other HIV antiretroviral drug
classes, and the individual drugs for the NNRTI class (as drugs of
this class showed a weak protective association [table S1, http://
links.lww.com/MD/B519]). The exposure was subsequently
subdivided into ART-treated and suppressed (HIV Ribo-nucleic
acid (RNA)50 copies/mL) or ART treated and nonsuppressed.
The univariable analysis was constructed to include variables
that most likely inﬂuence syphilis incidence based on the
literature and clinicians’ evaluation. The following covariates
were examined in the univariable models: square root trans-
formed CD4, CD8, and nadir CD4 cell count (lowest observed
CD4 since enrollment). In addition, baseline CD4 cell count
<200 (binary), log transformed HIV RNA copies/mL, smoking
(binary), recreational drug use (binary, reﬂecting no drug use=0,
and any intravenous drug use 1), reporting of condomless sex
with a stable or occasional partner (binary), ethnicity (binary,
white, and non-white), age at infection (continuous per 5 years),
and education (binary, attended a higher education institution).
The inclusion criteria for the multivariable analysis were based
on clinical relevance, signiﬁcance in the univariable analysis (P
value 0.1), and in case of highly correlated variables, only 1
representative was chosen (e.g., for HIV RNA viral load and
ART, ART was chosen as it is the explanatory variable of
interest). The included variables were immunity markers (CD4
and nadir CD4), behavioral markers (condomless sex with
occasional partner, testing rate per year), ART, demographics
(age at infection, ethnicity, and last center of follow-up), and
calendar year (to account for the time trends of incidence).
For sensitivity analyses, the associations were estimated using a
Weibull hazard function and Cox proportional hazard models.
Analyses were conducted in Stata 14.1 (Stata Corp., Texas,
United States) and R 3.3.1 (R Foundation for Statistical
Computing, Vienna, Austria).
4. Results
A total of 3575 individuals were routinely tested for syphilis at
least once, following a negative baseline test between 2004 and
2014 (median observation start year 2005, inter-quartile range
IQR 2004–2007) (Table 1). There were 226 incident syphilis
cases reported in 19,041 person-years. The incidence rate was
26.8 cases per 1000 person-years for MSM (95% conﬁdence
interval [95% CI] 23.5–30.8), 1.3 (0.49–3.5) for IDU, and 1.8
(1.1–3.0) for HET. This corresponded to 207 (92%) syphilis
cases in MSM, 4 (2%) in IDU, and 15 (6%) in HET.
During the study period (2004–2014), we found a signiﬁcant
increase of syphilis incidence over time (Pearson correlation
between annual incidence and year 0.9, P<0.01; Figs. 1 and 2,
and Tables 2 and 3). We did not observe a clear elevation of
syphilis incidence immediately after the year 2008 (the year of the
so-called Swiss statement[32]). However, the incidence rate of
syphilis increased 2-fold by 2012, and a similar trend was
reﬂected in the hazard of acquiring syphilis estimated by the
model described in Section 3 (Tables 2 and 3). In addition, we
observed that the MSM population is most affected by syphilis
and accounts for themajority of incident cases (92%). Finally, the
Table 1
General characteristics of eligible MSM SHCS patients at enrollment.
Patients with an incident
syphilis infection (N=207)
Patients with no incident syphilis
infection (N=1312)
CD4+ cell count, cells/mm3, median (IQR) 473 (342–621) 460 (324–625)
Age at infection, median (IQR) 42 (37–48) 46 (40–52)
HIV-1 RNA, log10 copies/mL, median (IQR) 2.8 (0.0–4.56) 1.7 (0.0–4.2)
Ethnicity (N [%])
White 187 (90) 1207 (92)
Non-White 20 (10) 105 (8)
Year of observation start, median (IQR) 2006 (2004–2008) 2005 (2004–2008)
Percentage smokers at infection or censoring 48 40
Infection year, median (IQR) 2011 (2009–2013) –
Testing rate per year, median (IQR) 1.2 (0.9–1.6) 1.2 (1.0–1.4)
HIV = human immune deﬁciency virus.
Figure 1. The number of unique Swiss HIV Cohort study patients tested per
year and the number of syphilis tests they underwent are shown for the years
2005 to 2014. The number of syphilis cases is shown in 1000 patient-years per
transmission group. The vertical axis is log-scaled and dots below 1 represent
years with 0 syphilis cases. HET = heterosexual, IDU = intravenous drug use,
MSM = men who have sex with men.
Shilaih et al. Medicine (2017) 96:2 www.md-journal.com
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number of cases in IDU has remained constantly low over time,
while that of HET seems to be increasing; yet the overall low
number of cases does not allow for conclusive assessment,
particularly because 2 of the 19 syphilis-infected patients in the
IDU and HET transmission group identify as bisexual and
another individual of the 19 identiﬁes as homosexual.
Hereafter, we focus on the MSM population, as it is the group
with the highest incidence, and in which public health
interventions would have the strongest impact.
We observed no association between being on ART and
syphilis incidence (univariable hazard ratio [HR] 1.2, 95% CI
0.8–1.9). Breaking down ART treatment into individual drug
classes revealed that NNRTI could potentially have a protective
association against syphilis (HR 0.9, 95% CI 0.7–1.2; table S1,
http://links.lww.com/MD/B519). Indeed, we found that nevira-
pine (NVP) was associated with lower syphilis incidence
(multivariable HR 0.5, 95% CI 0.2–1.0) (Table 3). We also
observed that the protective association of NVP was tightly
coupled to viral load suppression (plasma RNA50) (NVP and
suppressed HR 0.4, 95% CI 0.2–0.9). No protective effect of
NVP was present in nonsuppressed patients on NVP (HR 1.0,
95%CI 0.1–7.9). Furthermore, the effect of NVP did not seem to
bemediated by immunemarkers as the association remained even
after adjusting for these variables (among others, Tables 2 and 3).
Neither Ritonavir-boosted nor nonboosted PI was associated
with syphilis incidence.
A decrease in syphilis incidence with increasing age was the
only demographic association (univariable HR 0.7, 95% CI
0.7–0.8); neither ethnicity nor education had an effect (Table 3).
On the behavioral side, risk behavior was generally associated
with higher incidence of syphilis. A history of condomless sex
with an occasional partner increased the hazard of acquiring
syphilis (univariable HR 4.6, 95% CI 3.1–6.50). Interestingly,
condomless sex with a stable partner was also associated with
higher incidence of syphilis (univariable HR 1.4, 95% CI
0.9–2.1); however, this association was not statistically signiﬁ-
cant. While individuals who reported being in a stable
partnership were less likely to engage in condomless sex with
occasional partners (odds ratio 0.24, 95% CI 0.24–0.25), 12%
reported such behavior. We also observed that intravenous drug
use (compared to no drug use) was associated with higher
incidence of syphilis (HR 11.6, 95%CI 2.1–65). However, only 9
individuals reported intravenous drug use for 0.07% of the total
observation time; hence, this covariate was not included in the
multivariable model as a marker of risk behavior. Moreover,
smoking was associated with an increased syphilis incidence, yet
the association was not statistically signiﬁcant (HR 1.3, 95% CI
0.9–1.7, Tables 2 and 3). Finally, individuals who tested more
frequently for syphilis also had a higher propensity to be infected
(univariable HR 2.7, 05% CI 1.9–3.8).
The immunological status represented by square root trans-
formed CD4, CD8, and nadir CD4 cell count was not associated
with the hazard of contracting syphilis (Tables 2 and 3).
The estimates were qualitatively similar when using a Cox
proportional hazard model or a Weibull hazard function for the
current model (results not shown).
5. Discussion
In this study, we report on the factors associated with syphilis
incidence in the era of highly effective ART in the SHCS. Most
prominently, we observed a steady increase of syphilis incidence,
with the highest burden falling on MSM. We showed that risk
behavior (condomless sex or drug use) and young age were all
associated with a higher risk of contracting syphilis, while NVP
treatment was associated with a lower risk.
We observed no association between being on ART and
syphilis incidence, which implies that immune reconstitution does
not provide signiﬁcant protection against syphilis. The protective
effect of NVP was only present in individuals with viral
suppression, that is, only NVP that achieved viral suppression
(50 HIV RNA copies/mL) conferred a protective effect. This
suggests the necessity of consistent drug administration and
Table 3
Multivariable analysis of factors associated with syphilis incidence
in MSM.
HR 95% CI
NRTI 1.48 0.83 2.64
Other drugs 1.38 0.80 2.39
PI 1.19 0.77 1.83
NVP 0.45 0.21 0.96
EFV 1.02 0.64 1.63
RPV
∗
0.00 0.00 Inf
ETV 0.68 0.34 1.37p
CD4 0.99 0.95 1.02p
Nadir CD4 1.00 0.97 1.04
Condomless sex with an occasional partner 3.74 2.61 5.36
Calendar year 1.22 1.14 1.31
Age at infection (per 5 years) 0.75 0.69 0.81
Ethnicity 0.88 0.55 1.41
Center 1.30 0.96 1.77
Testing rate per year 1.80 1.28 2.53
EFV = efavirenz, ETV = etravirine, HR = hazard ratio, NRTI = nucleotide reverse transcriptase
inhibitors, NVP = nevirapine, other drugs = integrase and fusion inhibitors, PI = protease inhibitors,
RPV = rilpivirine.
∗
Few patients are on RPV, hence the lack of an estimate.
Table 2
Univariable analysis of factors associated with syphilis incidence
in MSM.
Variable HR 2.5% 97.5%
NRTI 1.41 0.91 2.20
NNRTI 0.87 0.65 1.17
Other drugs 1.49 0.93 2.40
PI 1.09 0.82 1.46
ART 1.20 0.77 1.86p
CD4 1.02 0.99 1.05p
CD8 1.01 0.99 1.03p
CD3 1.01 0.99 1.03p
Nadir CD4 1.04 1.01 1.07
Log10 HIV RNA 0.98 0.89 1.08
Smoking 1.25 0.94 1.67
Intravenous Drug use 11.63 2.09 64.90
Condomless sex with a stable partner 1.38 0.92 2.06
Condomless sex with an occasional partner 4.55 3.18 6.50
Testing rate per year 2.70 1.93 3.76
Age at infection (per 5 years) 0.70 0.65 0.76
Ethnicity (non-White) 1.26 0.79 2.00
Education (higher than high school) 1.23 0.75 2.04
Calendar year 1.24 1.17 1.31
Center (out of Zurich) 1.04 0.79 1.37
ART = antiretroviral treatment, HIV = human immune deﬁciency virus. HR = hazard ratio, NNRTI =
non-nucleotide reverse transcriptase inhibitors, NRTI = nucleotide reverse transcriptase inhibitors,
other drugs = integrase and fusion inhibitors, PI = protease inhibitors.
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adherence for NVP to exhibit its potential protective effect
against syphilis.
Generally, we observed a lower overall incidence rate of
syphilis in the SHCS than that of HIV-infected MSM in
Canada,[33] the Netherlands,[34] and the United States[22] (27
per 1000 person-years for the SHCS compared to 42, 46, and 62,
respectively). We also observed a consistent rise in syphilis
incidences in recent years; 25 to 35 per 1000 person-years
between 2009 and 2011 compared to 60 to 74 in 2012 to 2014
(Fig. 2). Similar increases have been reported in other
countries,[1,22,34] and syphilis incidence remains very high in
theMSM community. At the same time, there are more reports of
condomless sex in the SHCS[12] and in other countries.[13]
Condomless sex remains one of the strongest drivers of syphilis
incidence in the SHCS. Consequently, better risk reduction
measures are needed. For example, it has been shown that patients
who have already had an episode of syphilis are 3 timesmore likely
to be reinfected,[33] implying continued risky behavior tendencies
in some populations. Such individuals are prime targets for more
frequent screening andother supportive therapy.Weobserved that
individuals who get tested more frequently (i.e., more than once a
year during routine screening) are 2 to 3 times more likely to get
infected with syphilis. These individuals are probably screened
more often due to their self-reported risky sexual behavior (with
testing initiated either by themselves or by their clinician), which
underlines the importance of frequent testing in high-risk groups.
Several studies have demonstrated the beneﬁt of screening for
syphilis every 3 months compared to 6 or 12 months.[35] The
observation that younger age is associated with higher syphilis
incidence should help target intervention efforts.
Our ﬁndings are in line with the reported syphilis-incidence
trends in non-HIV-infected MSM in Switzerland (BAG Bulletin
2011–2014). This implies that the behavior leading to syphilis
infection is not exclusive to HIV-infected individuals. A high
syphilis incidence together with the untreated HIV-infected
individuals (mostly undiagnosed) could be one of the factors
contributing to the still relatively high rate of new HIV infections
seen in Switzerland, despite almost fulﬁlling the World Health
Organization 90-90-90 criteria.[36] Yet, the root cause of both
syphilis and HIV incidence remains condomless sex. As in our
earlier study of condomless sex in the SHCS,[12] it is clear that
condomless sex correlates strongly with a general increase of
incidence of sexually transmitted infections (STIs). One of the
challenges that any STI prevention measure in a high-risk
population will face is communicating that the efﬁcacy of HIV
treatment as prevention and pre-exposure prophylaxis does not
extend beyond HIV, and that one remains vulnerable to other
STIs by engaging in condomless sex. A recent meta-analysis
showed that MSM receiving pre-exposure prophylaxis were
between 11.2 and 44.6 times more likely to get infected with an
STI, with syphilis having the strongest likelihood (44.6).[37]
One factor that could beneﬁt from further investigation is the
study of the circulating syphilis strains of the past years. Multiple
reports indicate that there are several circulating Treponema
pallidum strains with different genetic proﬁles[38] (e.g., Azithro-
mycin-resistant variants[39,40]). This could imply that the increase
in syphilis incidence, while readily explainable by an increase in
condomless sex, could be further fueled by a shift in the circulating
strains of T. pallidum that are more transmissible or pathogenic
(unfortunately such data are not available in Switzerland).
To our knowledge, there are no known mechanistic effects for
NVP against T. palladium. Given the observational nature of
our study, one cannot exclude the contribution of unobserved
confounders to the observed association. Nonetheless, there are
reports of other antiretrovirals being effective against both gram-
positive and gram-negative bacteria (Shilaih et al submitted).
T. pallidum remains one of the bacteria that cannot be grown in
axenic medium and requires laborious infection of animals
(rabbits) to be studied; therefore, it is highly challenging to
evaluate the effect of NVP experimentally.
We strived to select a homogenous sample of individuals to
minimize demographic and behavioral inﬂuence on the associ-
ations (hence the focus onMSM); however, this does not rule out
the potential presence of other factors not accounted for by the
chosen covariates. In other words, we cannot rule out that the
observed NVP effect occurred because patients who receive NVP
are different from the overall study population in ways not
captured by the covariates included in the multivariable analysis.
Moreover, while the syphilis testing procedure as described in
Section 2 is considered the standard of care worldwide,[41] it is
known that false positives as well as false negatives could occur,
especially in HIV-infected individuals.[42,43]
This study demonstrates that syphilis incidence has been
continuously increasing in recent years with the main driver being
high-risk behavior. In addition, we demonstrate that ART
generally does not provide a protective effect against syphilis.
Given these ﬁndings, more frequent screening targeted for MSM
is needed to limit syphilis spread (and other STIs) and the
probably consequent increase of HIV infections. Moreover, we
found an unexpected but intriguing protective association of
NVP against syphilis incidence, which demands further investi-
gation—epidemiologically and potentially in other settings such
as prospective clinical trials. If proven effective, NVP could be
recommended to high-risk individuals for its potential to reduce
HIV transmission and syphilis acquisition.
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Figure 2. Teal-colored dots and conﬁdence intervals (CIs) represent the
incidence rate of syphilis in the Swiss HIV Cohort study between 2005 and
2014, cases per 1000 person-years (for easier trend visualization, the blue line
is a natural cubic spline ﬁtted to the incidence rate, the gray shaded region
shows the estimated 95% CI). The red dots show the absolute number of
incident cases per year (the red line represents a natural cubic spline ﬁtted to
the absolute number of cases).
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